Global Bird Flu Market, By Virus Type (H5N1, H7N9, H5N6, H5N8, H10N8, H9N2, Others), By Test Type (PCR Tests, ELISA Tests, Hemagglutination Assays, Virus Isolation Tests, Next Generation Sequencing, Others), By Treatment Type (Vaccines, Antiviral Medication, Immunomodulators, Others), By Animal Type (Chickens, Ducks, Geese & Swans, Pigeons, Guinea Fowls, Turkeys, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Dec 2023

Code : CMI6517

Pages :180

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Bird Flu Market- Recent Developments

Research and Development Activities

In October 2023, FluMap consortium, headed by the world-leading research team at the Animal and Plant Health Agency in U.K., discovered that Northern Gannets and Shag are showing signs of developing immunity to avian influenza. The top scientific research consortium has secured US$ 3.8 million additional funding for further research into avian influenza transmission due to continued risk of spread of disease.
In April 2023, The U.S. Department of Agriculture (USDA) announced the testing of a handful of vaccinations against the current strain of highly pathogenic avian influenza (HPAI), in the hopes of halting the spread of the nation's greatest bird flu outbreak in history. According to a U.S. DA spokesman, researchers with the U.S. DA's Agricultural Research Service (ARS) began evaluating four vaccine candidates in April, beginning with single-dose studies.
In September 2022, Wageningen Bioveterinary Research (WBVR) started a trial with bird flu vaccination. In the trial, vaccines against the current H5 viruses are tested in laying hens. This first vaccine trial is performed in the animal facilities in the high containment unit of WBVR. The modern vaccines were developed by three different pharmaceutical companies; the tested vaccines are based on different technologies.

Business Development Activities by Market Players

In August 2023, CSL Seqirus, a business of CSL, was selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to deliver one bulk lot of H5N8 A/Astrakhan antigen to the U.S. government. This gain of a bulk lot will increase BARDA's stockpile of vaccine to support rapid response in an associated avian influenza pandemic.
In April 2023, The U.S. Department of Agriculture (USDA) continues efforts on many fronts to mitigate the latest outbreak of highly pathogenic avian influenza (HPAI) in the U.S. This pervasive virus is carried in wild, migratory birds and typically peaks in the spring and summer months in the U.S. As part of U.S. DA’s commitment, on April 13, 2023, the department held a stakeholder roundtable with poultry industry leaders and state government officials to discuss the current and future HPAI strategy and opportunities for continued collaboration.
In March 2023, Virax Biolabs Group Limited, an innovative diagnostics company that focuses on the prevention, detection, and diagnosis of viral diseases, announced that it had entered into an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to markets accepting the CE mark, namely the European Union. The test kit is for the detection and differentiation of ribonucleic acid from AIV and the H5, H7 and H9 subtypes, including the H5N1 strain currently spreading in Europe.